Tag archives: pharma sector

Legal update: M&A in the pharma sector

Of counsel James Baillieu explores the pharma M&A horizon in PharmaTimes magazine. The pharma sector saw deal activity fall in 2017 compared to previous years. While the number of deals remained robust, their value was significantly lower due to fewer large acquisitions. Looking ahead, however, many expect deal levels to pick-up as Trump’s tax reforms … Continue reading

Trend report: increased M&A deal values across the Americas for Q1 2017

On April 25, Mergermarket released its Q1 2017 Regional Flash Reports describing the M&A climate, trends and developments throughout the Americas during the first quarter of 2017. The Canada’s Trend Report indicates that Canadian M&A has remained strong with 111 deals in Q1 2017 worth US$ 35.8bn. This is a robust start for 2017 as … Continue reading

A global overview of M&A activity: August 2016

MergerMarket Group recently published its September edition of Monthly M&A Insider which reported on mergers and acquisitions activity around the world for the month of August 2016. More than two thirds into the year, August was no exception to the recent rather sluggish growth in M&A activity, especially compared to the record-breaking year for M&A … Continue reading

$40 billion in deals in one day: is “big pharma” getting bigger?

In a single day last week, $40 billion worth of deals were announced in the pharmaceutical industry.  The jaw-dropping, combined value of the announced mergers and acquisitions has turned heads, and has prompted analysts to question the impetus behind these deals. The increased activity may come as a surprise to some, as recent changes by … Continue reading

A global overview of December 2015 M&A activity

According to Mergermarket’s December insider, November 2015 was a record setting month for M&A activity. By the end of the month, global M&A value reached US$3.9tn which surpassed the 2007 full year record by almost 6%. This record came on a drop in volume by 1,228 transactions which further cements 2015 as the year of … Continue reading

M&A activity in the pharmaceutical sector is driving the commercialization of new drugs

The global pharmaceutical sector has been rocked by several significant mergers and acquisitions in 2015: Indian generics firm Sun Pharma purchased GSK’s Australian opiates operations, citing the development of analgesics as a key growth opportunity US-based AbbVie acquired Pharmacyclics, with a central motivation being the acquisition of the blockbuster cancer drug Imbruvica US giant Pfizer … Continue reading

Sophisticated hackers may be trading with stolen M&A data

A recent report by security consulting firm FireEye reveals that a hacker group, referred to as FIN4, have infiltrated over 100 publicly traded companies and advisory firms since at least mid-2013 and are likely trading using inside information. FIN4’s ongoing hacking efforts particularly target the email accounts of individuals with access to non-public information about … Continue reading

Pharmaceutical M&A: strong performance expected to continue in 2015

In its December 2014 cover story, Financier Worldwide provides an overview of the factors in 2014 that provided, and will continue to provide, favorable conditions for the high value and volume of pharmaceutical mergers and acquisitions. In the first half of 2014 alone, there was a total value of $317.4 billion USD in M&A deals. … Continue reading

Megamergers in the pharma sub-sector: all systems go

Our April 29, 2014 blog post, M&A in the pharma sector: big deals are on the uptick, spoke to the significant increase in deal activity in Q1 2014 within the Pharma, Medical & Biotech sector and, most notably, within the pharmaceutical sub-sector. While there are critics who rely on conventional wisdom to question not only … Continue reading
LexBlog